Detalles de la búsqueda
1.
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
Haematologica
; 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-38497158
2.
Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
Biol Blood Marrow Transplant
; 22(11): 1983-1987, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27492792
3.
Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia.
Haematologica
; 100(6): 786-93, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25749825
4.
High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program.
Haematologica
; 98(11): 1718-25, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23753030
5.
Digital Guardian Angel Supported by an Artificial Intelligence System to Improve Quality of Life, Well-being, and Health Outcomes of Patients With Cancer (ONCORELIEF): Protocol for a Single Arm Prospective Multicenter Pilot Study.
JMIR Res Protoc
; 12: e45475, 2023 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37083563
6.
Toll-like receptor 4 suppression leads to islet allograft survival.
FASEB J
; 21(11): 2840-8, 2007 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-17475921
7.
Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia.
Mediterr J Hematol Infect Dis
; 6(1): e2014062, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25237475
Resultados
1 -
7
de 7
1
Próxima >
>>